Status:
COMPLETED
ALTROPANE® SPECT Imaging in Patients With Parkinson Disease
Lead Sponsor:
Molecular NeuroImaging
Collaborating Sponsors:
Institute for Neurodegenerative Disorders
Conditions:
Parkinson Disease
Eligibility:
All Genders
30+ years
Phase:
PHASE2
Brief Summary
After a screening evaluation including baseline clinical laboratory testing, a physical and neurological evaluation, subjects will be asked to undergo an injection of ALTROPANE® followed by up to 60 m...
Detailed Description
The underlying goal of this open label imaging study is to optimize the imaging outcome for ALTROPANE® in mild to moderate PD subjects. All study procedures will be conducted at the Institute for Neur...
Eligibility Criteria
Inclusion
- The participant is 30 years or older at time of PD diagnosis.
- Written informed consent is obtained.
- Participants have a clinical diagnosis of idiopathic Parkinson's disease of \< 7 years.
- Hoehn and Yahr stages I-III.
- Negative drug screen
Exclusion
- The participant has atypical or drug-induced Parkinson's disease.
- The participant has dementia.
- The participant has a clinically significant clinical laboratory value and/or clinically significant unstable medical or psychiatric illness.
- Treatment within the six months prior to screening with bupropion, methylphenidate, reserpine, alpha methyldopa, or amphetamine.
- The participant has a history of alcohol, narcotic, or any other drug abuse within the past 2 years.
- The participant has received an investigational drug within 60 days of screening visit.
- Pregnancy
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00397228
Start Date
November 1 2006
End Date
December 1 2011
Last Update
December 16 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Molecular NeuroImaging
New Haven, Connecticut, United States, 06510